Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

5 terminated/withdrawn out of 30 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

63%

19 trials in Phase 3/4

Results Transparency

0 of 17 completed trials have results

Key Signals

2 recruiting4 withdrawn

Enrollment Performance

Analytics

Phase 3

14(51.9%)

Phase 4

5(18.5%)

N/A

4(14.8%)

Phase 2

3(11.1%)

Phase 1

1(3.7%)

27Total

Phase 3(14)

Phase 4(5)

N/A(4)

Phase 2(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT07183748Phase 2Recruiting

Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression

Role: lead

NCT04882839Phase 2Recruiting

Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD

Role: lead

NCT02472899Completed

Biomarker Study for Alzheimer's Disease

Role: lead

NCT00146263Not ApplicableWithdrawn

Computerized Cognitive Training in the Elderly

Role: lead

NCT02298985Phase 4Completed

Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

Role: lead

NCT01663077Phase 4Completed

Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients

Role: collaborator

NCT02987842Not ApplicableUnknown

Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease

Role: lead

NCT02222220Phase 3Completed

Metoclopramide as Treatment of Clozapine-induced Hypersalivation

Role: lead

NCT01993316Not ApplicableUnknown

Neurofeedback Using TMS as an Assessment Tool

Role: lead

NCT01908452Phase 3Withdrawn

Pyridoxal Kinase Activity in Tardive Dyskinesia

Role: lead

NCT00189995Phase 3Withdrawn

Clozapine IM and Aggression in Schizophrenic Patients

Role: lead

NCT00141947Phase 3Unknown

Bexarotene Treatment in Schizophrenia

Role: lead

NCT00313417Phase 4Terminated

Creatine as a New Therapeutic Strategy in Depression

Role: collaborator

NCT01196624Phase 2Completed

Repetitive Transcranial Magnetic Stimulation With Or Without Traumatic Stimuli in Post Traumatic Stress Disorder (PTSD)

Role: lead

NCT01723033Unknown

Differences in Cognitive Performance and Brain Activity Between Patients With PTSD and OCD

Role: lead

NCT01020695Completed

Quantitative Electroencephalography (QEEG) and Low-resolution Electromagnetic Tomography (LORETA) Analysis in Post Traumatic Stress Disorder (PTSD) Patients

Role: lead

NCT00535574Phase 3Completed

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

Role: lead

NCT00534573Phase 3Completed

Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation

Role: lead

NCT00190021Phase 3Unknown

Donepezil Treatment of Psychotic Symptoms in Dementia Patients

Role: lead

NCT00192725Not ApplicableCompleted

Tryptophan Depletion in Acute Mania

Role: collaborator